OncoMatch/Clinical Trials/NCT06801730
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
Is NCT06801730 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Irinotecan liposome combined with bevacizumab for glioma.
Treatment: Irinotecan liposome combined with bevacizumab — With the optimization of the dosage form of irinotecan, the replacement of ordinary irinotecan with irinotecan liposomes should improve the safety and the expected efficacy. Therefore, an exploratory study on the treatment progress of irinotecan liposomes combined with bevacizumab for recurrent brain glioma should be conducted. To evaluate the efficacy and safety of irinotecan liposomes combined with bevacizumab in the treatment of progressive/recurrent brain glioma, so as to provide more treatment options for patients with brain glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: first-line therapy
patients with progress in first-line therapy, including postoperative recurrence, progress in first-line standard therapy, and patients unable to undergo surgery/radiotherapy
Cannot have received: irinotecan or irinotecan liposomes
no previous treatment with irinotecan or irinotecan liposomes
Lab requirements
Blood counts
Neutrophils (ANC) ≥1.5×10^9/L, platelets (PLT) ≥100×10^9/L, hemoglobin (Hb) ≥90g/L, white blood cells (WBC) ≥3.0×10^9/L, albumin (ALB) ≥32 g/L, and no bleeding tendency
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 ml/min (Cockroft-Gault)
Liver function
AST, ALT and alkaline phosphatase (ALP) ≤2.5× ULN, and ≤5×ULN when liver metastases occurred; Total bilirubin ≤1.5×ULN
Good bone marrow and organ function: ① Neutrophils (ANC) ≥1.5×10^9/L, platelets (PLT) ≥100×10^9/L, hemoglobin (Hb) ≥90g/L, white blood cells (WBC) ≥3.0×10^9/L, albumin (ALB) ≥32 g/L, and no bleeding tendency; ② AST, ALT and alkaline phosphatase (ALP) were all ≤2.5× upper limit of normal range (ULN), and ≤5×ULN when liver metastases occurred; Total bilirubin ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60 ml/min (calculated according to Cockroft-Gault);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify